Mersana Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Mersana Therapeutics

28/02/2025 13:43

Mersana Therapeutics Inc MRSN.OQ MRSN.O is expected to show a fall in quarterly revenue when it reports  results on March 3 for the period ending December 31 2024

The Cambridge Massachusetts-based  company is expected to report a 28.3% decrease in revenue to $7.673 million from $10.7 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Mersana Therapeutics Inc is for a loss of 16 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Mersana Therapeutics Inc is $5.00​, above​ its last closing price of $0.50. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.18
-0.18
-0.09
Beat
48.7
Jun. 30 2024
-0.17
-0.17
-0.20
Missed
-16.7
Mar. 31 2024
-0.18
-0.18
-0.16
Beat
11.6​
Dec. 31 2023
-0.12
-0.16
-0.16
Met
2.6
​​Sep. 30 2023
-0.35
-0.36
-0.27
Beat
25.4
Jun. 30 2023
-0.37
-0.44
-0.47
Missed
-6.5​
Mar. 31 2023
-0.40
-0.44
-0.52
Missed
-19.3
Dec. 31 2022
-0.47
-0.50
-0.44
Beat
12.8

This summary was machine generated February 28 at 13:43 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)